Georgia's Online Cancer Information Center

Kidney Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Kidney Cancer
Cancer Type = Kidney Cancer
There are currently 16 active Kidney Cancer clinical trials in Georgia.
1.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Phase 1b / 2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Cancer Type
Breast Cancer, Kidney Cancer, Unknown Primary
NCT ID
NCT03875313
Protocol IDs
CX-839-011
NCI-2019-02256
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04022343
Protocol IDs
Winship4643-19
NCI-2019-02253
IRB00110583
Treatment Sites (2)
6.
A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination With Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients With Low PD-L1 Expression
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCT ID
NCT03785925
Protocol IDs
18-214-10
NCI-2019-01752
CA045-012
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
8.
9.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
11.
12.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Cancer Type
Ewing Sarcoma, Kidney Cancer, Unknown Primary
NCT ID
NCT02867592
Protocol IDs
ADVL1622
NCI-2016-01258
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
14.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
Phase II Study of Front Line Therapy with Nivolumab and Salvage Nivolumab + Ipilimumab in Patients with Advanced Renal Cell Carcinoma
Cancer Type
Kidney Cancer
NCT ID
NCT03117309
Protocol IDs
2017-0010
NCI-2017-02166
GU16-260
CA209-669
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
Study of Renal Tumors in Pediatric Patients
Cancer Type
Kidney Cancer
NCT ID
NCT00898365
Protocol IDs
COG-AREN03B2
AREN03B2
Treatment Sites (4)
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.